Oxytetracycline/OVA

Oxytetracycline/OVA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with ovalbumin (OVA) . By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or destroy the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

Product Specifications

UNSPSC

12352200

Target

Biochemical Assay Reagents

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

[Oxytetracycline/OVA]

References & Citations

[1]Weiss AM, et al. Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021 Mar 18;11 (1) :6267.